Journal of Society of Preventive Korean Medicine (대한예방한의학회지)

Society of Preventive Korean Medicine (대한예방한의학회)
권호 표지

Effect of Jaeumkanghwatang (JEKHT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (2) - Oral Combination Treatment of Tamoxifen 50 mg/kg with JEKHT 100 mg/kg on JEKHT 6-day Repeated Pretreated Rats with 8-day Repeated Co-administration -

  • Park, Soo Jin (Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany University) ;
  • Kwak, Min A (Department of Internal Medicine, College of Korean Medicine, Daegu Haany University) ;
  • Park, Sung Hwan (Department of Surgery, Catholic University of Daegu School of Medicine) ;
  • Lee, Young Joon (The Medical Research center for Globalization of Herbal Formulation, College of Korean Medicine, Daegu Haany University) ;
  • Ku, Sae Kwang (Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany University)
  • Received : 2016.07.02
  • Accepted : 2016.07.14
  • Published : 2016.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : The effects of Jaeumkanghwatang (JEKHT) co-administration on the pharmacokinetics of tamoxifen were observed after oral combination treatment of tamoxifen 50 mg/kg with JEKHT 100 mg/kg on JEKHT 6-day repeated oral pretreated rats with 8-day repeated co-administration to confirm the effects of JEKHT co-administration on the pharmacokinetics of tamoxifen. Methods : Six days after pretreatment of JEKHT 100 mg/kg, tamoxifen 50 mg/kg was co-administered with JEKHT 100 mg/kg, once a day for 8 days within 5 min. The blood were collected at 30 min before administration, 30 min, 1, 2, 3, 4, 6, 8 and 24 hrs after end of first and last 8th tamoxifen treatment, and plasma concentrations of tamoxifen were analyzed using LC-MS/MS methods. PK parameters of tamoxifen ($T_{max}$, $C_{max}$, AUC, $t_{1/2}$ and $MRT_{inf}$) were analysis as compared with tamoxifen single administered. Results : Six-day repeated oral pretreatment of JEKHT and 8-day repeated oral co-administration of tamoxifen within 5 min did not influenced on the plasma concentrations and pharmacokinetic parameters of tamoxifen, oral bioavailability, as compared with tamoxifen single treated rats, except for some negligible effects. Conclusions : It is concluded that JEKHT did not influenced on the plasma concentrations and pharmacokinetic parameters, the oral bioavailability of tamoxifen. Therefore, it is considered that co-administration of JEKHT and tamoxifen will be provide an effective novel treatment regimen on the comprehensive and integrative medicine for breast cancer patients, if they showed favorable synergic effects on the pharmacodynamics or reduce the tamoxifen treatment related toxicity and side effects in future studies.

Keywords

References

  1. Kim SY, Suzuki N, Santosh Laxmi YR, Rieger R, Shibutani S. a-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chem Res Toxicol. 2003;16(9):1138-1144. https://doi.org/10.1021/tx0300131
  2. Notley LM, Crewe KH, Taylor PJ, Lennard MS, Gillam EM. Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its a-hydroxy and a,4-dihydroxy derivatives. Chem Res Toxicol. 2005;18(10):1611-1618. https://doi.org/10.1021/tx050140s
  3. Lien EA, Anker G, Lonning PE, Solheim E, Ueland PM. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res. 1990;50(18):5851-5857.
  4. Ritchie LD, Grant SM. Tamoxifen-warfarin interaction: the Aberdeen hospitals drug file. BMJ. 1989;298(6682):1253.
  5. Tenni P, Lalich DL, Byrne MJ. Life threatening interaction between tamoxifen and warfarin. BMJ. 1989;298(6666):93.
  6. Lamberts SW, Verleun T, Hofland L, Oosterom R. Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. J Clin Endocrinol Metab. 1986;63(6):1342-1347. https://doi.org/10.1210/jcem-63-6-1342
  7. Dowsett M, Pfister C, Johnston SR, Miles DW, Houston SJ, Verbeek JA, Gundacker H, Sioufi A, Smith IE. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res. 1999;5(9):2338-2343.
  8. Reid AD, Horobin JM, Newman EL, Preece PE. Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients. Breast Cancer Res Treat. 1992;22(2):153-156. https://doi.org/10.1007/BF01833345
  9. Dehal SS, Brodie AM, Kupfer D. The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy. Drug Metab Dispos. 1999;27(3):389-394.
  10. West CM, Reeves SJ, Brough W. Additive interaction between tamoxifen and rifampicin in human biliary tract carcinoma cells. Cancer Lett. 1990;55(2):159-163. https://doi.org/10.1016/0304-3835(90)90027-U
  11. Mani C, Gelboin HV, Park SS, Pearce R, Parkinson A, Kupfer D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab Dispos. 1993;21(4):645-656.
  12. Mani C, Pearce R, Parkinson A, Kupfer D. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis. 1994;15(12):2715-2720. https://doi.org/10.1093/carcin/15.12.2715
  13. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002;30(8):883-891. https://doi.org/10.1124/dmd.30.8.883
  14. Jung DY, Ha HK, Lee HY, Lee JA, Lee JK, Huang DS, Shin HK. Stimulation of the immune response by Yin-Tonifying formula. J Korean Oriental Med. 2010;31:112-123.
  15. Sekiya N, Hikiami H, Sakai S, Kainuma M, Goto H, Shibahara N, Shimada Y, Terasawa K. Experimental Application of Jiin-koka-to to Cases of Bronchial Asthma. Kampo Medicine. 2003;54(6):1097-1101. https://doi.org/10.3937/kampomed.54.1097
  16. Kim YK, Kim HJ, Kim WS, Park HJ, Moon G, Kim DW, Won JH. Inhibitory effect of Jaeumganhwa-tang on allergic inflammatory reaction. Korean J Orien Inter Med. 2004;25:174-182.
  17. Zheng H, Lee Y, Yoo H, Cho C. Case Study of a Breast Cancer Patient Accompanying with Hot Flush by Tamoxifen Whose Condition Was Improved by Jayeumganghwa-tang. Korean J Orien Inter Med. 2010;6:395-400.
  18. Kwak MA, Park SJ, Park SH, Lee YJ, Ku SK. Effect of Jaeumkanghwatang (JEKHT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (1) - Single Oral Combination Treatment of Tamoxifen 50 mg/kg with JEKHT 100 mg/kg within 5 min -. J Korean Med. 2016;37(2):1-11. https://doi.org/10.13048/jkm.16016
  19. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. Oxford: Taylor & Francis; 1982.
  20. Bailer AJ. Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm. 1988;16(3):303-309. https://doi.org/10.1007/BF01062139
  21. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm. 1978;6(6):539-546. https://doi.org/10.1007/BF01062108
  22. Fox JG, Cohen BJ, Loew FM. Laboratory Animal Medicine. Orlando: Academic Press. Inc.; 1984.
  23. Tajima Y, Horiuchi S. Biological reference data book on experimental animals. Tokyo: Soft Science; 1989.
  24. Adam HK, Gay MA, Moore RH. Measurement of tamoxifen in serum by thin-layer densitometry. J Endocrinol. 1980;84(1):35-42. https://doi.org/10.1677/joe.0.0840035
  25. Adam HK, Patterson JS, Kemp JV. Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer Treat Rep. 1980;64(6-7):761-764.
  26. Fabian C, Sternson L, Barnett M. Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. Cancer Treat Rep. 1980;64(6-7):765-773.
  27. Jordan VC, Bain RR, Brown RR, Gosden B, Santos MA. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer Res. 1983;43(3):1446-1450.
  28. Murphy C, Fotsis T, Pantzar P, Adlercreutz H, Martin F. Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM). J Steroid Biochem. 1987;26(5):547-555. https://doi.org/10.1016/0022-4731(87)90006-9
  29. Jordan VC. Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res Treat. 1982;2(2):123-138. https://doi.org/10.1007/BF01806449
  30. Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet RM, Chen G, Boyiri T, Amin S, Lazarus P. Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007;35(11):2006-2014. https://doi.org/10.1124/dmd.107.017145
  31. AstraZeneca Pharmaceuticals. Nolvadex (tamoxifen citrate) prescribing information. Wilmington, DE: 2003 June.
  32. Hall WA, Doolittle ND, Daman M, Bruns PK, Muldoon L, Fortin D, Neuwelt EA. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas. J Neurooncol. 2006;77(3):279-284. https://doi.org/10.1007/s11060-005-9038-4
  33. Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol. 2006;24(4):675-680. https://doi.org/10.1200/JCO.2005.02.3515
  34. Grilli S. Tamoxifen (TAM): the dispute goes on. Ann Ist Super Sanita. 2006;42(2):170-173.
  35. Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, Salvioni A, Travaglini R, Oliviero P, D'Aiuto G, Gulisano M, Gucciardo G, del Turco MR, Pizzichetta MA, Conforti S, Bonanni B, Boyle P, Veronesi U, Italian Tamoxifen Study G. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation. 2005;111(5):650-656. https://doi.org/10.1161/01.CIR.0000154545.84124.AC
  36. Osman KA, Osman MM, Ahmed MH. Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going? Expert Opin Drug Saf. 2007;6(1):1-4. https://doi.org/10.1517/14740338.6.1.1
  37. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000;64(2):165-176. https://doi.org/10.1023/A:1006426132338
  38. Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ. Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage. 2004;21(1):364-371. https://doi.org/10.1016/j.neuroimage.2003.08.037
  39. Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol. 1999;17(5):1488-1492. https://doi.org/10.1200/JCO.1999.17.5.1488
  40. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A, Group AT. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006;100(3):273-284. https://doi.org/10.1007/s10549-006-9260-6
  41. Karimian E, Chagin AS, Gjerde J, Heino T, Lien EA, Ohlsson C, Savendahl L. Tamoxifen impairs both longitudinal and cortical bone growth in young male rats. J Bone Miner Res. 2008;23(8):1267-1277. https://doi.org/10.1359/jbmr.080319
  42. Wilson SC, Knight PG, Cunningham FJ. Evidence for the involvement of central conversion of testosterone to oestradiol-17b in the regulation of luteinizing hormone secretion in the cockerel. J Endocrinol. 1983;99(2):301-310. https://doi.org/10.1677/joe.0.0990301
  43. Nalbandian G, Paharkova-Vatchkova V, Mao A, Nale S, Kovats S. The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation. J Immunol. 2005;175(4):2666-2675. https://doi.org/10.4049/jimmunol.175.4.2666
  44. Berstein LM, Wang JP, Zheng H, Yue W, Conaway M, Santen RJ. Long-term exposure to tamoxifen induces hypersensitivity to estradiol. Clin Cancer Res. 2004;10(4):1530-1534. https://doi.org/10.1158/1078-0432.CCR-0433-03
  45. Rousset-Jablonski C, Thalabard JC, Gompel A. Tamoxifen contraindicated in women with hereditary angioedema? Ann Oncol. 2009;20(7):1281-1282.